A prospective double-blind randomized controlled study to examine the effects of Korean red ginseng on biological aging indicators and antioxidants in Korean postmenopausal women.
- Conditions
- Not Applicable
- Registration Number
- KCT0006506
- Lead Sponsor
- Yonsei University Health System, Gangnam Severance Hospital
- Brief Summary
There were 63 participants, of whom 33 received KRG and 30 received a placebo. mtDNA copy number (KRG group: 1.58 ± 2.05, placebo group: 0.28 ± 2.36, p = 0.023) and TAS (KRG group: 0.11 ± 0.25 mmol/L, placebo group: -0.04 ± 0.16 mmol/L, p = 0.011) increased and fatigue severity score (KRG group: -7 ± 12, placebo group: -1 ± 11, p = 0.033) decreased significantly more in the KRG group than the placebo group.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Female
- Target Recruitment
- 63
1. A person who voluntarily agrees to participate in this trial after explaining the characteristics of this clinical trial and signs the IRB-approved consent form
2. Postmenopausal women aged between 46 and 69 at the time of obtaining consent
3. Patients approved by the attending physician to participate in the study
4. Those who can complete the study without participating in other interventional studies (drugs, diet, exercise) during the study period
5. Patients without restrictions on participation in physical activity during the study period
6. Patients who can understand and use Korean naturally
1. Premenopausal women under the age of 46 or over 69
2. Current Smoker
3. Alcohol (2 times a week / 3 or more drinks a day)
4. Poorly controlled hypertension (SBP>180, DBP>100)
5. Poorly controlled diabetes (fasting blood sugar >200)
6. Diagnosed with liver disease, AST, ALT more than 3 times the upper limit, or kidney disease (serum creatinine >2.0 mg/dL)
7. Those who have been diagnosed with cancer or are undergoing treatment
8. Those who have been diagnosed with cardiovascular disease or are taking medications
9. Those taking other health supplements
10. Patients with visual, hearing and speech impairments that may affect the examination
11. Others who are considered to be unable to participate in this study when judged by the person in charge of clinical research
13. Those taking hormonal drugs
Study & Design
- Study Type
- Interventional Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method DNA telomere length, mitochondria DNA copy number, total antioxidant status, total oxidative status
- Secondary Outcome Measures
Name Time Method clinical symptoms questionnaire and complete blood count, lipid profile, liver enzyme(aspartate aminotransferase, alanine aminotransferase, gamma-glutamyltransferase ), blood uria nitrate, creatinine, glucose, urine analysis, body composition